Optic neuritis: Difference between revisions
Line 99: | Line 99: | ||
Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4]. | Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4]. | ||
===Common Risk Factors=== | ===Common Risk Factors=== | ||
*Common risk factors in the development of | * Common risk factors in the development of optic neuritis include: | ||
* | ** '''Age''' | ||
** | *** Optic neuritis most often affects adults between the ages of 15 and 49.<ref name="pmid3105615" /> | ||
** | ** '''Sex''' | ||
** | *** Women are much more likely to develop optic neuritis than men are.<ref name="pmid3414716" /> | ||
** '''Race''' | |||
*** Optic neuritis usually affects individuals of the Caucasians race eight times more frequently than Blacks and Asians.<ref name="pmid3178158" /><ref name="pmid17967837" /><ref name="pmid2124032" /><ref name="pmid9482360" /> | |||
*** Black populations individuals are less likely to develop optic neuritis.<ref name="pmid3178158" /><ref name="pmid17967837" /><ref name="pmid2124032" /><ref name="pmid9482360" /> | |||
** '''Genetic mutation''' | |||
*** | |||
===Less Common Risk Factors=== | ===Less Common Risk Factors=== |
Revision as of 17:34, 12 November 2018
WikiDoc Resources for Optic neuritis |
Articles |
---|
Most recent articles on Optic neuritis Most cited articles on Optic neuritis |
Media |
Powerpoint slides on Optic neuritis |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Optic neuritis at Clinical Trials.gov Trial results on Optic neuritis Clinical Trials on Optic neuritis at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Optic neuritis NICE Guidance on Optic neuritis
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Optic neuritis Discussion groups on Optic neuritis Patient Handouts on Optic neuritis Directions to Hospitals Treating Optic neuritis Risk calculators and risk factors for Optic neuritis
|
Healthcare Provider Resources |
Causes & Risk Factors for Optic neuritis |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Overview
Historical Perspective
Discovery
- Optic neuritis was first discovered by von Graefe and Nettleship, in late nineteenth century when ophthalmoscopy became part of the ophthalmic examination.[1]
- The association between systemic sclerosis and optic neuritis was made by the early 1900's but there was much controversy and misunderstanding about its differential diagnosis, pathogenesis, and possible treatment.[1]
- Optic neuritis was first distinguished from infectious,hereditary, toxic, nutritional, and ischemic optic neuropathies during the twentieth century.[1]
- During late twentieth century, the development of MRI and the results from recent clinical trials, discovered the relationship between optic neuritis and multiple sclerosis.[1]
Classification
Optic neuritis may be classified into atypical or typical subtypes based on its clinical features.[2]
- Atypical optic neuritis entails clinical manifestations that deviate from classic pattern of optic neuritis features.[3]
- Atypical features to consider include:[3]
- Lack of pain
- Simultaneous or near-simultaneous onset
- Lack of response to or relapse upon tapering from corticosteroids
- Optic neuritis due nerve head or peripapillary hemorrhages
Pathophysiology
Pathogenesis
- The exact pathogenesis of optic neuritis is not completely understood.[4][5]
- But It is likely due to some inflammatory process which leads to delayed type IV hypersensitivity reaction induced by released cytokines and other inflammatory mediators from activated peripheral T-cells which can cross the blood brain barrier and cause destruction of myelin, neural cell death and axonal degeneration.[4][5]
- In addition to involvement of the myelin sheath (white matter), latest technologies such as optical coherence tomography (OCT) suggest involvement of axons (gray matter) in this process.[4][5]
- Findings suggestive of optic neuritis in microscopic histopathological analysis include:[6]
- Reduced axon counts
- Optic atrophy
- Inflammation
- Demyelination
- Axonal loss
- Intracellular neurofilaments
Causes
- The exact cause of optic neuritis is unknown.[7][8][9]
- But It is likely due invasion of the immune system to the myelin, resulting in inflammation and damage to the myelin.
The following autoimmune are associated with optic neuritis:[7][8][9]
- Multiple sclerosis:
- Multiple sclerosis is the first main cause of optic neuritis.[8]
- 50% of patients with multiple sclerosis finally develop optic neuritis.[9]
- Neuromyelitis optica
- In Neuromyelitis optica, inflammation recurs in the optic nerve and spinal cord.
- Infections:
Differentiating Optic Neuritis from other Diseases
Optic neuritis must be differentiated from other diseases that cause sudden eye pain and vision loss such as:[2]
- Leber’s Hereditary Optic Neuropathy (LHON)[2] which results from point mutations in mitochondrial DNA and subsequent mitochondrial dysfunction, causing bilateral central vision loss.[10]
- Nonarteritic Anterior Ischemic Optic Neuropathy (AION)[2]
- It is the most common form of ischemic optic neuropathy and the second most common optic neuropathy.
- It is more common in patients over the age of 50 years with vasculopathic risk factors such as:
Epidemiology and Demographics
Incidence
Age
- Optic neuritis commonly affects patients between the ages of 15 and 49.[13]
Race
- Optic neuritis usually affects individuals of the Caucasians race eight times more frequently than Blacks and Asians.[7][14][15][16]
- Black populations individuals are less likely to develop optic neuritis.[7][14][15][16]
Gender
- Women are more commonly affected by optic neuritis than men.[2]
Region
- The incidence of optic neuritis is highest in populations located at higher latitudes such as:[7][17][18]
- Northern United States
- Northern and Western Europe
- New Zealand and Southern Australia
Risk Factors
There are no established risk factors for [disease name].
OR
The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].
OR
Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Common Risk Factors
- Common risk factors in the development of optic neuritis include:
Less Common Risk Factors
- Less common risk factors in the development of [disease name] include:
- [Risk factor 1]
- [Risk factor 2]
- [Risk factor 3]
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
Symptoms
Physical Examination
Laboratory Findings
Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
References
- ↑ 1.0 1.1 1.2 1.3 Volpe NJ (December 2001). "Optic neuritis: historical aspects". J Neuroophthalmol. 21 (4): 302–9. PMID 11756864.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Kliethermes MA (July 1988). "Working parents in two-pharmacist marriages". Am J Hosp Pharm. 45 (7): 1500. PMID 3414716.
- ↑ 3.0 3.1 Gaier ED, Boudreault K, Rizzo JF, Falardeau J, Cestari DM (December 2015). "Atypical Optic Neuritis". Curr Neurol Neurosci Rep. 15 (12): 76. doi:10.1007/s11910-015-0598-1. PMID 26467052.
- ↑ 4.0 4.1 4.2 Hoorbakht H, Bagherkashi F (2012). "Optic neuritis, its differential diagnosis and management". Open Ophthalmol J. 6: 65–72. doi:10.2174/1874364101206010065. PMC 3414716. PMID 22888383.
- ↑ 5.0 5.1 5.2 Toosy AT, Mason DF, Miller DH (January 2014). "Optic neuritis". Lancet Neurol. 13 (1): 83–99. doi:10.1016/S1474-4422(13)70259-X. PMID 24331795.
- ↑ Taniguchi S, Kawano T, Kakunaga T, Baba T (May 1986). "Differences in expression of a variant actin between low and high metastatic B16 melanoma". J. Biol. Chem. 261 (13): 6100–6. PMID 3700386.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 Marechal F, Berthiot G, Deltour G (1988). "Serum levels of CA-50, CA-19.9, CA-125, CA-15.3, enolase and carcino-embryonic antigen in non neoplastic diseases of the lung". Anticancer Res. 8 (4): 677–80. PMID 3178158.
- ↑ 8.0 8.1 8.2 Bourdial J (April 1969). "[Otorhinolaryngologic action in asthmatics]". Maroc Med (in French). 49 (523): 209–17. PMID 5398737.
- ↑ 9.0 9.1 9.2 Balcer LJ (March 2006). "Clinical practice. Optic neuritis". N. Engl. J. Med. 354 (12): 1273–80. doi:10.1056/NEJMcp053247. PMID 16554529.
- ↑ Fujimori H (December 1973). "[Pulmonary tuberculosis--keypoints in nursing of pregnant and puerperal patients]". Josanpu Zasshi (in Japanese). 27 (12): 40–3. PMID 4492634.
- ↑ Rodriguez M, Siva A, Cross SA, O'Brien PC, Kurland LT (February 1995). "Optic neuritis: a population-based study in Olmsted County, Minnesota". Neurology. 45 (2): 244–50. PMID 7854520.
- ↑ Percy AK, Nobrega FT, Kurland LT (February 1972). "Optic neuritis and multiple sclerosis. An epidemiologic study". Arch. Ophthalmol. 87 (2): 135–9. PMID 5057861.
- ↑ 13.0 13.1 Self SG, Grossman EA (September 1986). "Linear rank tests for interval-censored data with application to PCB levels in adipose tissue of transformer repair workers". Biometrics. 42 (3): 521–30. PMID 3105615.
- ↑ 14.0 14.1 14.2 14.3 Bhigjee AI, Moodley K, Ramkissoon K (November 2007). "Multiple sclerosis in KwaZulu Natal, South Africa: an epidemiological and clinical study". Mult. Scler. 13 (9): 1095–9. doi:10.1177/1352458507079274. PMID 17967837.
- ↑ 15.0 15.1 15.2 15.3 Mbonda E, Larnaout A, Maertens A, Appel B, Lowenthal A, Mbede J, Evrard P (1990). "Multiple sclerosis in a black Cameroonian woman". Acta Neurol Belg. 90 (4): 218–22. PMID 2124032.
- ↑ 16.0 16.1 16.2 16.3 Phillips PH, Newman NJ, Lynn MJ (February 1998). "Optic neuritis in African Americans". Arch. Neurol. 55 (2): 186–92. PMID 9482360.
- ↑ Shams PN, Plant GT (September 2009). "Optic neuritis: a review". Int MS J. 16 (3): 82–9. PMID 19878630.
- ↑ Kurtzke JF (July 1985). "Optic neuritis or multiple sclerosis". Arch. Neurol. 42 (7): 704–10. PMID 4015470.